Breaking Finance News

United Therapeutics (NDAQ:UTHR) price target upped to $105.00, released a report earlier today by Jefferies & Co

Only yesterday United Therapeutics (NDAQ:UTHR) traded 0.15% higher at $129.20. UTHR’s 50-day average is $123.71 and its two hundred day average is $126.44. With the last stock price close up -4.84% relative to the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.03% over the same time. 85,954 shares of the stock were exchanged, down from an average trading volume of 567,085

Indicating a possible downside of -0.19%, Jefferies & Co increased the stock price target of United Therapeutics (NDAQ:UTHR) to $105.00

Previously on 04/27/2017, Wedbush released a statement about United Therapeutics (NDAQ:UTHR) reduced the target price from $229.00 to $213.00. At the time, this indicated a possible upside of 0.76%.

See Chart Below

United Therapeutics (NDAQ:UTHR)

United Therapeutics has a 52 week low of $110.90 and a 52 week high of $169.89 with a P/E ratio of 13.95 The company’s market cap is currently $0.

In addition to Jefferies & Co reporting its target price, a total of 11 firms have issued a report on the stock. The consensus target price is $140.09 with three equity analysts rating the company a strong buy, three equity analysts rating the stock a buy, 6 brokerages rating the stock a hold, 1 analyst rating the company a underperform, and lastly zero analysts rating the stock a sell.

General Information About United Therapeutics (NDAQ:UTHR)

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.